Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1All patients in the study will be treated with ocrelizumab1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
2ANA001XHCl (Syntagon) or VEXA-04 (Patheon)----1件: 156
3Behavioral: 50 patients will have a Free Choice between Filgotinib and anti TNF1件: Filgotinib1件: D10871 1件: JAK1 💬27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
4Behavioral: Clinical characteristics of AMS patients----1件: 17
5Behavioral: PAT sessions----1件: 6
6Behavioral: Physical Activity Together for PwMS and their CGs (PAT-MS)----1件: 13
7Behavioral: pre DBS patients responding to the DBS-PS scale----1件: 6
8BIIL 284 BS, high dose, adult patients----1件: 299
9BIIL 284 BS, high dose, pediatric patients----1件: 299
10BIIL 284 BS, low dose, adult patients----1件: 299
11BIIL 284 BS, low dose, pediatric patients----1件: 299
12BIIL 284 BS, medium dose, adult patients----1件: 299
13BIIL 284 BS, medium dose, pediatric patients----1件: 299
14Buprenorphine Transdermal Patch1件: Buprenorphine2件: D00836 ,
D07132 		2件: OPRK1,
OPRM1 💬		3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 46
15Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients----1件: 2
16CF patients with a G551D mutation and treated with Ivacaftor1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
17Cryopreserved EFS-ADA LV transduced patient CD34+ cells----1件: 65
18Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells----1件: 65
19Diagnostic Test: blood drawing in patients with WAS----1件: 65
20Dietary Supplement for PKU patients----1件: 240
21EF1aS-ADA lentiviral vector transduced patient CD34+ cells----1件: 65
22ETIMS (EDC-fixed autologous PBMCs coupled with 7 immunodominant myelin peptides in MS patients)----1件: 13
23Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector----1件: 65
24Exelon 4.6 mg/24 h transdermal patch1件: Rivastigmine (Synonym: Sandoz Rivastigmine Patch 5)2件: D02558 ,
D03822 		1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
25Exelon 9.5 mg/24 h transdermal patch1件: Rivastigmine (Synonym: Sandoz Rivastigmine Patch 5)2件: D02558 ,
D03822 		1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
26Exelon Patch1件: Rivastigmine (Synonym: Sandoz Rivastigmine Patch 5)2件: D02558 ,
D03822 		1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
27Exelon Patch (rivastigmine transdermal system)1件: Rivastigmine (Synonym: Sandoz Rivastigmine Patch 5)2件: D02558 ,
D03822 		1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
28Exelon path transdermal1件: Rivastigmine (Synonym: Sandoz Rivastigmine Patch 5)2件: D02558 ,
D03822 		1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
29Fentanyl transdermal patch1件: Fentanyl (Synonym: Mylan-fentanyl Matrix Patch)2件: D00320 ,
D01399 		1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 46
30Gamma-secretase/Notch signalling pathway inhibitor RO4929097----1件: 74
31Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg1件: Golimumab1件: D04358 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97
32Growth hormone replacement therapy in growth hormone deficient patients only.1件: Somatotropin1件: D02691 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬1件: 78
33HP-3000 (ropinirole hydrochloride patch)1件: Ropinirole2件: D00784 ,
D08489 		3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
34HP-3000(ropinirole hydrochloride patch)1件: Ropinirole2件: D00784 ,
D08489 		3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
35Intervention for incipient patients at low risk of disease progression----1件: 66
36Intervention for patients at high risk of disease progression----1件: 66
37Lidocaine patch 5%1件: Lidocaine (Synonym: Menthocin Patch with Lidocaine - Strong)3件: D00358 ,
D02086 ,
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 13
38Long term follow up in all patients who received SAR422459 in previous study TDU13583----1件: 301
39Loxoprofen sodium hydrogel patch1件: Loxoprofen1件: D08149 2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 271
40Neupro 2 mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
41Neupro 2mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
42Neupro 2mg/24h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
43Neupro 4 mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
44Neupro 4mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
45Neupro 4mg/24h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
46Neupro 4Mg/24Hr Transdermal Patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
47Neupro 6 mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
48Neupro 6mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
49Neupro 6mg/24h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
50Neupro 8 mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
51Neupro 8mg/24h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
52Nicotine patch1件: Nicotine (Synonym: Nicotine Transdermal Patches)3件: D03365 ,
D05156 ,
D05157 		16件: CHRNA1,
CHRNA10,
CHRNA2,
CHRNA3,
CHRNA4,
CHRNA5,
CHRNA6,
CHRNA7,
CHRNA9,
CHRNB1,
CHRNB2,
CHRNB3,
CHRNB4,
CHRND,
CHRNE,
CHRNG 💬		7件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases 💬2件: 6, 84
53Nicotine transdermal patch1件: Nicotine (Synonym: Nicotine Transdermal Patches)3件: D03365 ,
D05156 ,
D05157 		16件: CHRNA1,
CHRNA10,
CHRNA2,
CHRNA3,
CHRNA4,
CHRNA5,
CHRNA6,
CHRNA7,
CHRNA9,
CHRNB1,
CHRNB2,
CHRNB3,
CHRNB4,
CHRND,
CHRNE,
CHRNG 💬		7件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases 💬1件: 6
54Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi4件: Epoprostenol,
Iloprost,
Macitentan,
Selexipag		5件: D00106 ,
D01337 ,
D02721 ,
D09994 ,
D10135 		3件: EDNRA,
EDNRB,
PTGIR 💬		10件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
55Other: At-home natalizumab treated MS patient1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
56Other: Histone acetylation profiles of cells of SRT patients with CREBBP mutations----1件: 102
57Other: Neupro 4 mg / 24 Hr. Transdermal Patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
58Other: Observation of Ocrelizumab as Treatment in RRMS Patients1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
59Other: The patients' parents have to complete the VINELAND II adaptive behavior scales scoring, The Sleep Disturbance Scale for Children (SDSC) and Horne & Ostberg Circadian Typology Questionnaire----1件: 149
60Other: Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.----1件: 215
61Oxycodone by patient-controlled analgesia (PCA)1件: Oxycodone3件: D03783 ,
D05312 ,
D05462 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 46
62PAT----3件: 6, 13, 160
63PAT-001, 0.1%----1件: 160
64PAT-001, 0.2%----1件: 160
65Patient Current Care----1件: 46
66Patient treated with DMARD----1件: 46
67Patients will be randomized to receive EHP-101----1件: 51
68Patients' existing non-steroidal anti-inflammatory drug (NSAID) at approved doses----1件: 46
69PD patients H&Y=1.5-2 Medications OFF----1件: 6
70PD patients H&Y=1.5-2 Medications ON----1件: 6
71PD patients H&Y=3 Medications OFF----1件: 6
72PD patients H&Y=3 Medications ON----1件: 6
73Pilocarpine microneedle patch1件: Pilocarpine3件: D00525 ,
D02200 ,
D05478 		2件: CHRM2,
CHRM3 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 299
74Rituximab, observational study amon patients with active RA1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
75Rivastigmin Luye Transdermal Patches - 4.6mg/24h----1件: 6
76Rivastigmine Luye Transdermal Patch- 9.5mg/24h1件: Rivastigmine (Synonym: Sandoz Rivastigmine Patch 5)2件: D02558 ,
D03822 		1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
77Rivastigmine Patch 9.5 cm21件: Rivastigmine (Synonym: Sandoz Rivastigmine Patch 5)2件: D02558 ,
D03822 		1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
78Rivastigmine transdermal patch1件: Rivastigmine (Synonym: Sandoz Rivastigmine Patch 5)2件: D02558 ,
D03822 		1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬2件: 6, 13
79Rotigotine 4Mg/24Hrs Patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 127
80Rotigotine 6Mg/24Hrs Patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 127
81Rotigotine transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
82Rotigotine transdermal patch 2mg/24h(10cm2)1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
83Rotigotine transdermal patch 4mg/24h (20cm2)1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
84Rotigotine transdermal patch 6mg/24h (30cm2)1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
85Rotigotine transdermal patch 8mg/24h (40cm2)1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
86Routine transdermal oestrogen patch----1件: 78
87Skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.----1件: 102
88SmartPill Motility System & PillCam Patency Capsule----1件: 299
89Speech pathology evaluation----1件: 78
90The effectiveness of Xeljanz in rheumatoid arthritis patients1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬		37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
91TNF-blockers suspension in patients with rheumatoid arthritis----1件: 46
92TOF repair with trans-annular patch VS preservation of PV----1件: 215
93Transduced patient CD34+ cells----1件: 65
94Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms1件: Lansoprazole1件: D00355 2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
95Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.1件: Bifenthrin---1件: 46